


Epioxa™ Billing and Coding

Peer-to-Peer Medical Review Notepad



If a patient has been denied coverage for epithelium-on corneal cross-linking treatment with Epioxa™, a peer-to-peer (P2P) medical review may be an appropriate next step before submitting a formal appeal, particularly where additional clinical clarification may address payer-specific criteria. Use this sheet to capture key details during your peer-to-peer call with a payer reviewer regarding an authorization for Epioxa.

This tear pad is designed to help healthcare providers prepare for that conversation by organizing key clinical documentation, outlining points to address during the discussion, and taking notes during the call. Information captured should be tailored based on the provider's clinical judgment and payer-specific requirements.

Patient Information

Patient Name, DOB:

Member ID & Group #:

PA #:

Clinical Summary

(Document as clinically appropriate and based on payer requirements)

Drug Name:

NDC / CPT® Code / HCPCS Code*:

Primary ICD-10-CM Code:

Corneal Topography/Tomography:

Pachymetry:

Clinical Notes:

Treatment History & Outcomes:

*Following the FDA approval of physician-administered therapies, physician providers may need to use temporary J-codes until unique drug codes are assigned. ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification. CPT Copyright 2025 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Call Logistics

Date & Time of Call:

Plan / Insurer:

Call Reference #:

Plan Reviewer Name / Specialty / Credentials:

Reviewer Contact Info:

INDICATION: EPIOXA HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA (riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O₂n™ System and the Boost Goggles®.

Please see Important Safety Information on the next page and accompanying [Full Prescribing Information](#) or visit [Epioxa.com](#).

Clinical Discussion Notes

Key medical facts to highlight:

Payer policy or guidelines referenced:

Reviewer questions:

Prescriber responses and supporting evidence discussed:

Outcomes & Next Steps

Approved

Authorization #:

Effective Dates:

Denied / Upheld

Reason:

If Denied

Next appeal level/instructions:

Additional documentation requested:

DISCLAIMER

This guide is provided by Glaukos for educational purposes only to support healthcare providers in preparing for peer-to-peer (P2P) medical reviews. It is not intended to direct clinical practice, dictate payer requirements, or guarantee coverage, payment, or appeal outcomes. Each payer's policies and review processes vary, and it is the healthcare provider's responsibility to determine appropriate documentation, clinical rationale, and next steps based on the patient's specific circumstances and payer requirements. The information contained herein was obtained from publicly available and third-party sources believed to be accurate at the time of publication but is subject to change without notice.

Indication and Important Safety Information

INDICATIONS AND USAGE

EPIOXA HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA (riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O₂n™ System and the Boost Goggles®.

IMPORTANT SAFETY INFORMATION

Contraindications

EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride (BAC) or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.

Warnings and Precautions

Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.

Adverse Reactions

The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.

Dosage and Administration

EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use.

EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use.

EPIOXA HD and EPIOXA are for use with the O₂n System and Boost Goggles only.

Refer to the [O₂n System Operator's Manual and Boost Goggles User Guide](#) for device instructions.

Please see full Prescribing Information for EPIOXA HD and EPIOXA at www.Epioxa.com.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.



Reach out to your Glaukos Reimbursement Liaison for claims submission and peer-to-peer medical review support

©2026 Glaukos Corporation. All rights reserved. Glaukos and Transforming Vision are registered trademarks of Glaukos Corporation.

PM-US-3298

Last updated: January 2026